Ruipu Bio and its holding subsidiary Huanan Bio jointly participated in the project "Innovation of Avian Influenza Vaccines and Key Technologies and Applications for Source Prevention and Control," which won the Second Prize of the National Science and Technology Progress Award. The project was led by South China Agricultural University, in collaboration with universities, national research institutions, and enterprises to tackle core challenges in avian influenza source prevention and control in China. It successfully created multiple world-first vaccine products and the world's first all-avian-origin reverse genetics vaccine development platform, achieving independent original breakthroughs across the entire chain of recombinant avian influenza vaccines. As the core industrialization implementation entities of the project, Ruipu Bio and Huanan Bio were fully responsible for technology transfer, process implementation, and market promotion. They have launched multiple avian influenza vaccine series such as Qinyuan, Qindun, and Youjinkang, all of which have obtained complete veterinary drug registration qualifications, with core performance consistently leading the industry. The vaccine series have been widely adopted nationwide and partially exported overseas. Ruipu Bio stated that the next step will be to continue increasing investment in original technology research and development, focus on tackling leading-edge veterinary biological product technologies, and support the green and high-quality development of the domestic livestock and poultry farming industry.
Tianjin Ringpu Bio TechWon Second Prize of National Science and Technology Progress Award for innovative avian influenza vaccines and platform.
Subsidiary Huanan Bio co-won the award and is core industrialization entity for the vaccine project.